Current Sepsis News and Events | Page 21

Current Sepsis News and Events, Sepsis News Articles.
Sort By: Most Relevant | Most Viewed
Page 21 of 21 | 839 Results
Chest 2003 registration open to media
Press registration is now underway for CHEST 2003, the annual international scientific assembly of the American College of Chest Physicians. CHEST 2003, taking place October 25-30 in Orlando, Florida, will feature the latest scientific developments in clinical chest medicine. World-renowned experts and up-and-coming investigators will present exceptional scientific sessions on a variety of topics, including asthma, critical care, lung cancer, sepsis, tobacco cessation, COPD, sleep medicine, pediatric pulmonology, disaster response, women's health, and thoracic surgery. (2003-09-15)

Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
MedImmune, Inc. and Critical Therapeutics, Inc. will collaborate on the research and development of antibodies and other drug products targeting the High Mobility Group Box Chromosomal Protein 1 (HMGB-1), which is believed to be involved in the tissue damage associated with a range of inflammatory illnesses, such as rheumatoid arthritis and sepsis. (2003-07-31)

Protein that fights bacteria and viruses cloned by Scripps scientists
Bacteria and viruses are completely different classes of pathogens, and while the detection systems are different, the actual immune defenses the body employs to clear the system of viral or bacterial infection are much the same. Now a team of researchers at The Scripps Research Institute (TSRI) has published a paper appearing in an upcoming issue of Nature that explains how pathogens as different as viruses and bacteria can have such a common bottom line. (2003-07-20)

Aspirin could reduce the risk of deadly infections
Adding to the long list of the benefits of aspirin, researchers have found that it is responsible for reducing toxic bacteria associated with serious infections. A study led by Dartmouth Medical School describes how salicylic acid-produced when the body breaks down aspirin-disrupts the bacteria's ability to adhere to host tissue, reducing the threat of deadly infections. (2003-07-17)

Sepsis drug fights infection, decreases hospital care over two year study
The drug drotrecogin alfa activated (DAA, activated protein C or Xigris) has been shown to effectively fight sepsis, reduce hospital care and prolong life, but it is underutilized. (2003-07-09)

FDG PET accurately evaluates infection and inflammation
Observing the wide and growing acceptance for using FDG PET to detect various kinds of cancer and monitor treatments, a group of researchers recently showed that FDG-PET is also extremely accurate for assessing infection and inflammation. (2003-06-23)

Sepsis could be underestimated in new-born babies
UK authors of a research letter in this week's issue of The Lancet suggest that the incidence of disease caused by group B streptococcal infection in babies is underestimated because the 'gold standard' methods for bacterial detection may result in falsely negative results. (2003-06-05)

Enzyme found in blood vessels likely target to treat lung injury
Scientists at Northwestern University have demonstrated that an enzyme vital to normal function of blood vessels also can be an Achilles heel during infection-induced or ventilator-induced lung injury. They believe that the enzyme holds significant potential as a drug discovery target for the treatment of acute lung injury. (2003-04-29)

TSRI scientists show that rare genetic mutations increase susceptibility to sepsis
A group of researchers from The Scripps Research Institute (TSRI) have discovered rare genetic mutations in a subset of people who come down with a particular kind of severe sepsis, an acute and often deadly disease. (2003-04-28)

Sepsis and sepsis-related deaths are on the increase in U.S., according to Emory and CDC study
The incidence of sepsis -- a severe, whole-body immune response to infection -- has increased by an annualized average of 8.7% a year in the U.S. over the past 22 years, according to research conducted on discharge data from 750 million patient hospitalizations nationwide between 1979 and 2000. The study was the most comprehensive investigation of sepsis epidemiology to date. (2003-04-16)

American Thoracic Society Journal news tips for March (first issue)
Newsworthy studies include research suggesting that: severe sepsis is major, costly health problem in young children with over 42,000 cases and 4,400 associated deaths per year in the U.S.; imported malaria is a growing health issue in many nonendemic countries, especially in Europe; and loud noises and frequent patient-care activities were responsible for only a small proportion of the observed sleep disruption in an intensive care unit. (2003-02-26)

Sepsis on the rise in the United States
Severe sepsis, the leading cause of death in America's non-coronary intensive care units, is a rapidly growing problem in the United States in terms of the number of patients afflicted and the complexity of their cases, report University of Pittsburgh researchers. Investigating trends in severe sepsis over a seven-year period, this study is the first to identify the changing epidemiology of the life-threatening disorder and its potential financial impact on intensive care units (ICUs). (2003-02-03)

Drotrecogin alfa (activated) is a cost-effective treatment for severe sepsis patients
The only FDA-approved drug for the treatment of severe sepsis, drotrecogin alfa (activated) (Xigris®), is a cost-effective treatment and has a cost-benefit ratio superior or similar to that of many widely used medical treatments, according to a University of Pittsburgh-led study published in the current issue of the journal Critical Care Medicine (January 2003, Vol. 31, No. 1). (2003-01-30)

Early promise of new treatment to reduce infection associated with chemotherapy
Authors of a fast-track study in this week's issue of The Lancet propose an alternative to antibiotics to treat infection associated with the use of chemotherapy for patients with blood cancer. (2003-01-23)

Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
Critical Therapeutics, Inc. (CTI) today announced that it has been awarded three U.S. patents covering methods to diagnose, predict the severity of and treat serious inflammatory diseases including sepsis, a bloodstream infection that is the nation's tenth leading cause of death. (2002-12-02)

The growing Staphylococcus aureus arsenal
In the November 18 issue of the Journal of Clinical Investigation Eric Brown and colleagues from the Texas A&M University Health Science Center further investigate the role of another interesting member of the S. aureus artillery. The MHC class II Analog Protein (Map) was shown to interfere with the function of T cells, a patient's most specific defense against foreign intruders, which appeared to promote the persistence and survival of S. aureus in infected mice. (2002-11-19)

LSUHSC research shows drug blocks enzyme that activates bacterial and viral toxins
A paper published in the December, 2002 issue of Infection and Immunity by a reasearch team at the Louisiana State University (LSU) Health Sciences Center in New Orleans provides clear evidence that the lethal toxins of such infectious bacteria as Pseudomonas and anthrax can be blocked by a drug developed at the LSU Health Sciences Center in New Orleans. The compound, called D6R (hexa-D-arginine), is a potent, stable, small molecule inhibitor of furin. (2002-11-18)

Sepsis vaccine proves protective in preliminary studies at The Scripps Research Institute
A group of researchers from The Scripps Research Institute (TSRI) have designed a vaccine that might be used to protect against the pernicious consequences of severe sepsis, an acute and often deadly disease that is estimated to strike 700,000 Americans a year and millions more worldwide. (2002-11-13)

American Thoracic Society news tips for November (first issue)
Newsworthy articles feature studies showing that: the efficacy of treatment for sepsis with anti-inflammatory agents depends on disease severity and risk of death; and spiral computed tomography of the chest in middle-aged smokers can detect two to four times more early lung cancer than can chest x-ray. (2002-11-05)

Intensive care treatment may be bad for your health
Two articles in the latest issue of Critical Care reveal how intensive care therapy may be beneficial in the short but not in the long term. Being treated in intensive care units may help critically ill patients survive but the quality of life - if they survive - is often severely impaired. It is unclear whether this impairment is a complication of the illness or a complication of therapy. (2002-08-12)

Researchers discover shift in organisms causing early-onset sepsis in low-birth-weight infants
Although the overall rate of early-onset sepsis in low-birth-weight newborns has not changed significantly over the past decade, researchers have discovered a recent shift in the organisms responsible for the systemic infection -- from primarily gram-positive bacteria to primarily gram-negative organisms, especially E. coli. The researchers, who believe further studies are needed to determine the reason for this change, consider it worrisome because of the high mortality rate associated with gram-negative infections. (2002-07-24)

Sepsis on the increase in U.S., according to Emory University and CDC study
The incidence of sepsis -- a severe, whole-body immune response to infection -- is increasing by an average of 16% a year in the U.S., according to research by investigators at Emory University School of Medicine and the Centers for Disease Control and Prevention (CDC). During the 20-year period from 1979 to 1999, the incidence of sepsis increased by more than 329%, from 78 to 259 cases per 100,000 people. (2002-05-21)

Molecular researchers to link heart & brain puzzle pieces at La Jolla conference
Topics include the convergence of heart and brain research, the critical shortage of physician-scienctists, and award presentations to prominent scientists and organizations. (2002-03-06)

American Thoracic Society Journal News Tips for July (Second Issue)
Newsworthy research appearing in the second of two July issues of the ATS journal includes studies showing that snorers and persons with obstructive sleep apnea (OSA) demonstrated upper airway sensory impairment which could trigger airway obstruction; an expert view that the airway sensory dysfunction could be caused by motor neuron lesions in some snorers and in most with OSA; the use of low-tidal ventilation in the critically-ill works equally well across all clinical subgroups. (2001-08-02)

The protective role of secreted CD14
The acute-phase response to the presence of LPS or other bacterial metabolites, a key aspect of host defense against infection, can unfortunately be fatal in its own right. The signaling pathway by which LPS elicits cytokine secretion by monocytes is now fairly well understood, but less is known about the protective mechanisms that limit the hazardous effects of LPS. (2001-08-01)

American Thoracic Society's 97th International Conference meets in San Francisco May 18 - 23
More than 5,500 original research presentations and hundreds of informational updates by international experts on the prevention, diagnosis, and treatment of lung cancer, asthma, allergies, tuberculosis, cystic fibrosis, genetics and lung disease, sleep disoders, chronic obstructive pulmonary disease, and critical care will be presented at the American Thoracic Society's International Conference in San Francisco May 18 - 23. (2001-05-09)

Countering the body's own harmful response to stroke
Scientists have found that a compound that recently made headlines for its potential in treating sepsis also holds promise in protecting brain cells from the damage caused by stroke. Activated Protein C helps snuff out a crucial step in the chain of events that can lead to the death of neurons. (2001-04-22)

From the heart
Premature and sick babies can die from bacterial infections that doctors often miss. But a new way of analysing a baby's heartbeat picks up these infections early enough to save lives. (2001-01-16)

FDA awards grant to metaphore pharmaceuticals to study septic shock in humans
The FDA has awarded a six-month $100,000 SBIR grant to MetaPhore Pharmaceuticals to study the dramatic and perplexing blood pressure drop that occurs during septic shock. Researchers from MetaPhore and Saint Louis University School of Medicine will study the levels of two key biological markers, one of which directly affects blood pressure, to see if what happens among human subjects correlates with the phenomenon they observed in recent animal studies. (2000-11-01)

Rheumatoid arthritis causes increased complications and health care costs in inpatient and outpatient settings
Rheumatoid arthritis patients seek outpatient care for symptoms unrelated to the musculoskeletal problems of their disease one-third of the time and face significantly longer hospital stays and more costly charges from complications and joint replacements, according to two studies from researchers at Zynx Health Inc., a subsidiary of Cedars-Sinai Health System, presented this week at the American College of Rheumatology annual meeting. (2000-10-28)

Proceedings of the National Academy of Science: animal study points to new method for halting life-threatening blood pressure decline during septis
The 700,000 Americans diagnosed with sepsis each year might have a better chance of reversing the dramatic and often fatal blood pressure drop that typically accompanies septic shock if new treatments are developed based on an animal study reported in today's Proceedings of the National Academy of Sciences. (2000-08-14)

FDA advisory committee recommends approval of Remicade® with methotrexate for reduction of joint damage in patients with rheumatoid arthritis
Centocor, Inc. said today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted unanimously to recommend approval of REMICADE® (infliximab) with methotrexate for reduction of structural damage in patients with rheumatoid arthritis. REMICADE with methotrexate is currently approved for treatment of rheumatoid arthritis in patients who have an inadequate response to methotrexate alone. (2000-07-11)

ENBREL® (etanercept) follow-up study in chronic heart failure presented at American College of Cardiology meeting
Continued treatment with the TNF inhibitor ENBREL (etanercept) was generally well-tolerated by the first twelve patients with advanced heart failure treated with the drug for nine months. In addition, there was evidence of sustained improvement in the New York Health Assessment (NYHA) class in these patients, according to results of a follow-up study. (2000-03-14)

ENBREL (etanercept) long-term clinical trial data
Data from patients receiving ENBREL (etanercept) for as long as 41 months were presented at the 63rd National Scientific Meeting of the American College of Rheumatology (ACR) today. (1999-11-16)

ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
Immunex Corporation announced today that the company has filed a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for ENBRELR (etanercept), seeking a new label for the drug to slow structural damage and to improve the signs and symptoms of early, active RA. (1999-07-15)

Unexpected target may unlock the door to fighting sepsis
Researchers at the University of Michigan and the University of Freiberg in Germany have demonstrated that blocking a substance the body normally produces to help fight bacteria shows great promise in animal studies as a potential treatment for sepsis. (1999-06-29)

Researchers Develop First Way To Immunize Against A Deadly Bacterium
Laboratory researchers have developed a new way to cripple a virulent class of microbes that have become increasingly resistant to antibiotics and continue to kill hundreds of thousands of hospital patients every year. (1999-03-30)

Knee Replacement Patients Who Have Dental Work Susceptible To Infection Years After Surgery
People who have total knee replacements and later undergo extensive dental work may be susceptible to knee infections years after their initial surgery, according to a study by Johns Hopkins physicians. (1997-12-04)

Preventing Perinatal Infections -- For Pennies
In a study of nearly 7,000 pregnant women, cleansing the birth canal with an inexpensive antiseptic solution dramatically reduced post-birth infections, hospitalizations and deaths, according to a study supported by the National Institutes of Health (NIH). (1997-08-19)

Page 21 of 21 | 839 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to